Evidence mapPaperPMID 11931721Full record

ReviewCurrent atherosclerosis reports2002

Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.

Thoralf Wendt, Loredana Bucciarelli, Wu Qu, Yan Lu, Shi Fang Yan, David M Stern, Ann Marie Schmidt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Epigenetics in the pathogenesis of diabetic nephropathy.Acta biochimica et biophysica Sinica · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Research Progress on Gestational Diabetes Mellitus and Endothelial Dysfunction Markers.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Thoralf WendtDivision of Surgical Science, Department of Surgery, Columbia University College of Physicians & Surgeons, 630 West 168th Street, P&S 17-401, New York, NY 10032, USA.
Loredana Bucciarelli
Wu Qu
Yan Lu
Shi Fang Yan
David M Stern
Ann Marie Schmidt
Columbia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence and severity of atherosclerosis is increased in patients with diabetes. Indeed, accelerated macrovascular disease in diabetic patients has emerged as a leading cause of morbidity and mortality in the United States and worldwide. Multiple investigations have suggested that there are numerous potential contributory factors that underlie these observations. Our laboratory has focused on the contribution of receptor for advanced glycation endproducts (RAGE) and its proinflammatory ligands, advanced glycation endproducts (AGEs) and S100/calgranulins in vascular perturbation, manifested as enhanced atherogenesis or accelerated restenosis after angioplasty. In rodent models of diabetic complications, blockade of RAGE suppressed vascular hyperpermeability, accelerated atherosclerotic lesion area and complexity in diabetic apolipoprotein E-deficient mice, and prevented exaggerated neointimal formation in hyperglycemic fatty Zucker rats subjected to injury of the carotid artery. In this review, we summarize these findings and provide an overview of distinct mechanisms that contribute to the development of accelerated diabetic macrovascular disease. Insights into therapeutic strategies to prevent or interrupt these processes are presented.

Indexed as

AnimalsArteriosclerosisDiabetes MellitusDiabetic AngiopathiesGlycation End Products, AdvancedHumansInflammationLeukocyte L1 Antigen ComplexLigandsMembrane ProteinsMiceModels, AnimalRatsReceptor for Advanced Glycation End ProductsReceptors, ImmunologicS100 ProteinsGlycation End Products, AdvancedLeukocyte L1 Antigen ComplexLigandsMembrane ProteinsReceptor for Advanced Glycation End ProductsReceptors, ImmunologicS100 Proteins

Identifiers

PMID11931721
OpenAlexW2024861061

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.